✨ Free AI Report
BeyondSpring Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BeyondSpring Inc.
Research Preview

BeyondSpring Inc.: Business Overview, Financials & Competitive Analysis

BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results sh...

Analyst-debate audio for BeyondSpring Inc.

AskCyborg analysts argue the bull and bear cases for BeyondSpring Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BeyondSpring Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Clinical validation in Phase 3 NSCLC trials provides near-term value inflection potential, but cash constraints require near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest BeyondSpring Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BeyondSpring Inc. Overview

Pro stress-test →

BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results showed plinabulin plus docetaxel achieved median OS of 10.8 vs 8.8 months in Asian NSCLC patients, demonstrating clinical proof-of-concept.

Strategic Profile

Pro stress-test →

Plinabulin's mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. BeyondSpring co-founded SEED Therapeutics (38% ownership) which closed a $30M Series A-3 with FDA and NMPA IND clearance.

Competitive Landscape

Pro stress-test →

In NSCLC immunotherapy resistance space, few approved options exist despite 60% of patients developing resistance. Competitors include established checkpoint inhibitor companies (Merck, Bristol-Myers Squibb) and other IO combinations in development. BeyondSpring's dendritic cell maturation mechanism differentiates from conventional approaches.

Industry Context

BeyondSpring Inc. operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation.

Key facts

Founded: 2010 · Headquarters: Florham Park, New Jersey, US

What the analysts stress-tested

The top findings that survived the multi-agent debate for BeyondSpring Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BeyondSpring Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pembrolizumab + ChemotherapyPD-1 checkpoint inhibitor with docetaxel for NSCLC→Nivolumab + IpilimumabDual checkpoint inhibitor combination for cancer→DocetaxelStandard-of-care chemotherapy baseline→

Compare BeyondSpring Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BeyondSpring Inc. operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation research →
NEW · MCP server

Ask your AI assistant about BeyondSpring Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BeyondSpring Inc. and its top competitor on Cyborg Score”
“What did BeyondSpring Inc. do this quarter?”
“Is BeyondSpring Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BeyondSpring Inc. do?+
BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results sh...
What is BeyondSpring Inc.'s Cyborg Score?+
BeyondSpring Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BeyondSpring Inc.'s main competitors?+
Named competitors include Pembrolizumab + Chemotherapy, Nivolumab + Ipilimumab, Docetaxel. The full competitive landscape is in the AskCyborg report.
How can I get the full BeyondSpring Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BeyondSpring Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BeyondSpring Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group